In short
Clinical trials are investigating SONLICROMANOL HYDROCHLORIDE in people with long COVID. These studies are looking at whether it can improve fatigue and how well it works compared with placebo, which is an inactive look-alike treatment. The main target population is adults with post-COVID symptoms, especially fatigue.
Key points
- Clinical trials of SONLICROMANOL HYDROCHLORIDE are studying long COVID, with a focus on fatigue. The main trial listed is a Phase 2, randomized, double-blind, placebo-controlled study. It plans to enroll 80 people and compares SONLICROMANOL HYDROCHLORIDE with placebo. The main result being measured is fatigue symptoms at week 13 using the FAS. This means the study is mainly asking whether the treatment can lower tiredness in people with post-COVID symptoms.
Trial overview
The listed study of SONLICROMANOL HYDROCHLORIDE is a randomized, double-blind, placebo-controlled Phase 2 trial in people with long COVID. It is an interventional study, which means the researchers assign a treatment and then measure the results.
The trial is authorised and plans to enroll 80 participants. Its brief summary says the study is looking at reduction of post-COVID related fatigue measured with the FAS at week 13.
Who is being studied
The target condition is long COVID, also called post-COVID symptoms in the study summary. The main symptom being studied is fatigue, which means ongoing tiredness or low energy.
This means the trial is focused on people whose symptoms continue after a COVID-19 infection, especially those affected by persistent fatigue.
Study design and treatment groups
The trial is randomized, so participants are assigned to study groups by chance. It is also double-blind, which means neither the participants nor the study team know who receives the active treatment or the placebo during the study.
The comparison is between SONLICROMANOL HYDROCHLORIDE and placebo, an inactive look-alike treatment used to help show whether the study drug has a real effect. The intervention list includes Sonlicromanol tablets and a placebo, and also lists Sonlicromanol 180 mg by buccal use.
What is being measured
The primary outcome is fatigue symptoms measured at week 13 by the FAS. A primary outcome is the main result the researchers want to study.
The FAS is a fatigue assessment scale, which is a tool used to measure how severe tiredness is. In simple terms, the study wants to see whether SONLICROMANOL HYDROCHLORIDE can improve fatigue more than placebo after 13 weeks.
Trial status and size
The study status is Authorised, which means it has approval to proceed. With 80 planned participants, this is a small Phase 2 study designed to give an early answer about possible benefit in long COVID fatigue.
Because the trial is still in Phase 2, the main goal is to learn more about whether the treatment may help and to continue evaluating it in a limited group of patients.